pSivida Corp Announces Commercial Launch of ILUVIEN® in Germany With First Patient Treated

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida Corp. (NASDAQ:PSDV- News), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that ILUVIEN®, the first sustained release pharmaceutical product for the treatment of chronic diabetic macular edema (DME), is now commercially available in Germany. pSivida’s licensee Alimera Sciences reported that the first patient has been treated following the commercial launch in Germany.

Help employers find you! Check out all the jobs and post your resume.

Back to news